The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate unwanted immune responses in people, increasing the chances of side effects and ...
The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback